Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 1.04 [0.85, 1.27] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 1.09 [0.90, 1.33] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | important | - |
DCR | 1.12 [0.72, 1.75] | | > 1 | | 0% | 1 study (1/-) | 69.1 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 1.07 [0.67, 1.70] | | > 1 | | 0% | 1 study (1/-) | 61.2 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.80 [0.35, 1.79] | | < 1 | | 0% | 1 study (1/-) | 70.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 1.33 [0.93, 1.90] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.32 [0.70, 2.46] | | < 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 1.54 [0.89, 2.68] | | < 1 | | 0% | 1 study (1/-) | 6.1 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.39 [0.94, 2.06] | | < 1 | | 0% | 1 study (1/-) | 5.2 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.34 [0.22, 0.52] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.61 [0.39, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.5 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 3.93 [0.18, 87.52] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.97 [0.40, 2.39] | | < 1 | | 0% | 1 study (1/-) | 52.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Alopecia TRAE (grade 3-4) | 0.98 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.34 [0.11, 1.10] | | < 1 | | 0% | 1 study (1/-) | 96.4 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 2.47 [0.47, 12.85] | | < 1 | | 0% | 1 study (1/-) | 14.2 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.65 [0.11, 3.91] | | < 1 | | 0% | 1 study (1/-) | 68.1 % | NA | not evaluable | | non important | - |
Dermatitis acneiform TRAE (grade 3-4) | 0.98 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.65 [0.11, 3.91] | | < 1 | | 0% | 1 study (1/-) | 68.1 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.47 [0.24, 8.87] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.98 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.49 [0.02, 14.58] | | < 1 | | 0% | 1 study (1/-) | 65.9 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.12 [0.01, 2.29] | | < 1 | | 0% | 1 study (1/-) | 91.8 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.49 [0.02, 14.58] | | < 1 | | 0% | 1 study (1/-) | 65.9 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.98 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.08 [0.01, 0.60] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.01, 5.40] | | < 1 | | 0% | 1 study (1/-) | 81.2 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.98 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.98 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.98 [0.02, 49.37] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.96 [0.18, 21.75] | | < 1 | | 0% | 1 study (1/-) | 29.3 % | NA | not evaluable | | non important | - |